Literature DB >> 8093218

Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain.

E Fenouillet1, I Jones, B Powell, D Schmitt, M P Kieny, J C Gluckman.   

Abstract

To examine the role of the glycans of human immunodeficiency virus type 1 transmembrane glycoprotein gp41, conserved glycosylation sites within the env sequence (Asn-621, Asn-630, and Asn-642) were mutated to Gln. The mutated and control wild-type env genes were introduced into recombinant vaccinia virus and used to infect BHK-21 or CD4+ CEM cells. Mutated gp41 appeared as a 35-kDa band in a Western blot (immunoblot), and it comigrated with the deglycosylated form of wild-type gp41. Proteolytic cleavage of the recombinant wild-type and mutant forms of the gp160 envelope glycoprotein precursor was analyzed by pulse-chase experiments and enzyme-linked immunosorbent assay: gp160 synthesis was similar whether cells were infected with control or mutated env-expressing recombinant vaccinia virus, but about 10-fold less cleaved gp120 and gp41 was produced by the mutated construct than the control construct. The rates of gp120-gp41 cleavage at each of the two potential sites appeared to be comparable in the two constructs. By using a panel of antibodies specific for gp41 and gp120 epitopes, it was shown that the overall immunoreactivities of control and mutated gp41 proteins were similar but that reactivity to epitopes at the C and N termini of gp120, as present on gp160 produced by the mutated construct, was enhanced. This was no longer observed for cleaved gp120 in supernatants. Both gp120 proteins, from control and mutated env, were expressed on the cell surface under a cleaved form and could bind to membrane CD4, as determined by quantitative immunofluorescence assay. In contrast, and despite sufficient expression of env products at the cell membrane, gp41 produced by the mutated construct was unable to induce membrane fusion. Therefore, while contradictory results reported in the literature suggest that gp41 individual glycosylation sites are dispensable for the bioactivity and conformation of env products, it appears that such is not the case when the whole gp41 glycan cluster is removed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093218      PMCID: PMC237347     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2.

Authors:  Y Morikawa; J P Moore; A J Wilkinson; I M Jones
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

2.  Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.

Authors:  E O Freed; D J Myers; R Risser
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

3.  Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity.

Authors:  L Dirckx; D Lindemann; R Ette; C Manzoni; D Moritz; J Mous
Journal:  Virus Res       Date:  1990-12       Impact factor: 3.303

4.  Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.

Authors:  J P Moore; J A McKeating; I M Jones; P E Stephens; G Clements; S Thomson; R A Weiss
Journal:  AIDS       Date:  1990-04       Impact factor: 4.177

5.  Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro.

Authors:  Y Morikawa; H A Overton; J P Moore; A J Wilkinson; R L Brady; S J Lewis; I M Jones
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

6.  Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus.

Authors:  S Chakrabarti; T Mizukami; G Franchini; B Moss
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

7.  Expression and characterization of a functional human immunodeficiency virus envelope glycoprotein in insect cells.

Authors:  D E Wells; R W Compans
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

8.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

Authors:  C K Leonard; M W Spellman; L Riddle; R J Harris; J N Thomas; T J Gregory
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

9.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein.

Authors:  P L Earl; B Moss; R W Doms
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

10.  Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.

Authors:  E Fenouillet; J C Gluckman; E Bahraoui
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

View more
  8 in total

1.  Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Authors:  James M Binley; Yih-En Andrew Ban; Emma T Crooks; Dirk Eggink; Keiko Osawa; William R Schief; Rogier W Sanders
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

2.  Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication.

Authors:  W E Johnson; J M Sauvron; R C Desrosiers
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Evolution of a simian immunodeficiency virus pathogen.

Authors:  P Edmonson; M Murphey-Corb; L N Martin; C Delahunty; J Heeney; H Kornfeld; P R Donahue; G H Learn; L Hood; J I Mullins
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  The role of calcium and N-linked glycans in the oligomerization and carbohydrate binding properties of human immunodeficiency virus external envelope glycoprotein.

Authors:  M Haidar; N Seddiki; J C Gluckman; L Gattegno
Journal:  Glycoconj J       Date:  1994-04       Impact factor: 2.916

5.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120.

Authors:  P B Fischer; G B Karlsson; T D Butters; R A Dwek; F M Platt
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  Mapping of domains on HIV envelope protein mediating association with calnexin and protein-disulfide isomerase.

Authors:  Marie-Jeanne Papandréou; Rym Barbouche; Régis Guieu; Santiago Rivera; Jacques Fantini; Michel Khrestchatisky; Ian M Jones; Emmanuel Fenouillet
Journal:  J Biol Chem       Date:  2010-03-04       Impact factor: 5.157

Review 7.  Novel approaches to inhibit HIV entry.

Authors:  Chukwuka A Didigu; Robert W Doms
Journal:  Viruses       Date:  2012-02-21       Impact factor: 5.048

8.  Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection.

Authors:  Gama P Bandawe; Darren P Martin; Florette Treurnicht; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson
Journal:  Virol J       Date:  2008-11-24       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.